Clinical Trials Directory

Trials / Recruiting

RecruitingNCT02961413

A Prospective Cohort Study on Drug-induced Liver Injury in China(DILI-P)

A Multi-center, Prospective, Non-interventional Cohort Study on Drug Induced Liver Injury in Mainland China

Status
Recruiting
Phase
Study type
Observational
Enrollment
10,000 (estimated)
Sponsor
Drug Induced Liver Disease Study Group · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

This is a multi-center, prospective, non-interventional cohort study . Its primary objectives are: 1. assess DILI patients' clinical characteristics, disease progression and influencing factors in clinical practice; 2. learn about suspected drug caused DILI,rechallenging, liver biochemical abnormalities mode, etc.

Detailed description

The main purpose of this study is to understand patients with DILI clinical outcome and influencing factors in China's second and tertiary general hospitals (including Western medicine hospital, Chinese medicine hospital andIntegrated traditional Chinese and Western Medicine Hospital) and vulnerabilities of drug-induced liver injury specialist hospital (tuberculosis hospital, Pulmonary, etc.) in mainland. The main purpose 1. assess the DILI patients' clinical outcomes and influencing factors in the real world; 2. learn about suspected drug caused DILI,rechallenging, liver biochemical abnormalities mode, etc. Secondary objectives 1. assess the compliance of the DILI practice to the 2015 vision of the DILI guidelines in china.; 2. evaluate the histological features of DILI patients; 3. assessment DILI characteristics, prognosis and influencing factors in specific populations(such as the elderly, children with underlying liver disease background, etc.)

Conditions

Timeline

Start date
2016-04-01
Primary completion
2030-12-01
Completion
2030-12-01
First posted
2016-11-11
Last updated
2025-05-04

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02961413. Inclusion in this directory is not an endorsement.